These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32694991)

  • 1. Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery.
    Hinkson IV; Madej B; Stahlberg EA
    Front Pharmacol; 2020; 11():770. PubMed ID: 32694991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMPL: A Data-Driven Modeling Pipeline for Drug Discovery.
    Minnich AJ; McLoughlin K; Tse M; Deng J; Weber A; Murad N; Madej BD; Ramsundar B; Rush T; Calad-Thomson S; Brase J; Allen JE
    J Chem Inf Model; 2020 Apr; 60(4):1955-1968. PubMed ID: 32243153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine Learning and Artificial Intelligence: A Paradigm Shift in Big Data-Driven Drug Design and Discovery.
    Pasrija P; Jha P; Upadhyaya P; Khan MS; Chopra M
    Curr Top Med Chem; 2022; 22(20):1692-1727. PubMed ID: 35786336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of artificial intelligence to enhance phenotypic drug discovery.
    Malandraki-Miller S; Riley PR
    Drug Discov Today; 2021 Apr; 26(4):887-901. PubMed ID: 33484947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery.
    Ekert JE; Deakyne J; Pribul-Allen P; Terry R; Schofield C; Jeong CG; Storey J; Mohamet L; Francis J; Naidoo A; Amador A; Klein JL; Rowan W
    SLAS Discov; 2020 Dec; 25(10):1174-1190. PubMed ID: 32495689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial intelligence to deep learning: machine intelligence approach for drug discovery.
    Gupta R; Srivastava D; Sahu M; Tiwari S; Ambasta RK; Kumar P
    Mol Divers; 2021 Aug; 25(3):1315-1360. PubMed ID: 33844136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public-private partnerships to revitalize psychiatric drug discovery.
    Brady LS; Potter WZ
    Expert Opin Drug Discov; 2014 Jan; 9(1):1-8. PubMed ID: 24308355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities.
    Gangwal A; Ansari A; Ahmad I; Azad AK; Kumarasamy V; Subramaniyan V; Wong LS
    Front Pharmacol; 2024; 15():1331062. PubMed ID: 38384298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public-Private Partnerships in Lead Discovery: Overview and Case Studies.
    Gottwald M; Becker A; Bahr I; Mueller-Fahrnow A
    Arch Pharm (Weinheim); 2016 Sep; 349(9):692-7. PubMed ID: 27335205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generative chemistry: drug discovery with deep learning generative models.
    Bian Y; Xie XQ
    J Mol Model; 2021 Feb; 27(3):71. PubMed ID: 33543405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AI-Driven Enhancements in Drug Screening and Optimization.
    Serghini A; Portelli S; Ascher DB
    Methods Mol Biol; 2024; 2714():269-294. PubMed ID: 37676604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Design-to-Device Pipeline for Data-Driven Materials Discovery.
    Cole JM
    Acc Chem Res; 2020 Mar; 53(3):599-610. PubMed ID: 32096410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial Intelligence for Drug Discovery: Are We There Yet?
    Hasselgren C; Oprea TI
    Annu Rev Pharmacol Toxicol; 2024 Jan; 64():527-550. PubMed ID: 37738505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An
    Prieto-Martínez FD; Fernández-de Gortari E; Medina-Franco JL; Espinoza-Fonseca LM
    Artif Intell Life Sci; 2021 Dec; 1():. PubMed ID: 35475037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine-designed biotherapeutics: opportunities, feasibility and advantages of deep learning in computational antibody discovery.
    Wilman W; Wróbel S; Bielska W; Deszynski P; Dudzic P; Jaszczyszyn I; Kaniewski J; Młokosiewicz J; Rouyan A; Satława T; Kumar S; Greiff V; Krawczyk K
    Brief Bioinform; 2022 Jul; 23(4):. PubMed ID: 35830864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial Intelligence for Autonomous Molecular Design: A Perspective.
    Joshi RP; Kumar N
    Molecules; 2021 Nov; 26(22):. PubMed ID: 34833853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerating Biocatalysis Discovery with Machine Learning: A Paradigm Shift in Enzyme Engineering, Discovery, and Design.
    Markus B; C GC; Andreas K; Arkadij K; Stefan L; Gustav O; Elina S; Radka S
    ACS Catal; 2023 Nov; 13(21):14454-14469. PubMed ID: 37942268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions.
    Vatansever S; Schlessinger A; Wacker D; Kaniskan HÜ; Jin J; Zhou MM; Zhang B
    Med Res Rev; 2021 May; 41(3):1427-1473. PubMed ID: 33295676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomaterialomics: Data science-driven pathways to develop fourth-generation biomaterials.
    Basu B; Gowtham NH; Xiao Y; Kalidindi SR; Leong KW
    Acta Biomater; 2022 Apr; 143():1-25. PubMed ID: 35202854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four disruptive strategies for removing drug discovery bottlenecks.
    Ekins S; Waller CL; Bradley MP; Clark AM; Williams AJ
    Drug Discov Today; 2013 Mar; 18(5-6):265-71. PubMed ID: 23098820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.